What is the role of oxymetazoline in the treatment of rosacea?

Updated: Jun 03, 2021
  • Author: Agnieszka Kupiec Banasikowska, MD; Chief Editor: William D James, MD  more...
  • Print

Another topical alpha agonist, oxymetazoline, was approved in 2017 for persistent facial erythema associated with rosacea in adults. Approval was based on two randomized clinical trials (n=885) that compared the active drug with the cream vehicle. Once-daily topical application of oxymetazoline cream 1% was proven to reduce persistent facial erythema associated with rosacea through 12 hours. The primary efficacy endpoint was at day 29 and defined as the proportion of patients with at least a 2-grade reduction in erythema (improvement) from baseline on both the clinician erythema assessment (CEA) and subject self-assessment (SSA) (composite success). [25]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!